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Angiogenesis (neovascularization) plays a crucial role in a variety of physiological and pathological conditions
including cancer, cardiovascular disease, and wound healing. Vascular endothelial growth factor (VEGF) is a critical
regulator of angiogenesis. Multiple VEGF receptors are expressed on endothelial cells, including signaling receptor
tyrosine kinases (VEGFR1 and VEGFR2) and the nonsignaling co-receptor Neuropilin-1. Neuropilin-1 binds only the
isoform of VEGF responsible for pathological angiogenesis (VEGF165), and is thus a potential target for inhibiting VEGF
signaling. Using the first molecularly detailed computational model of VEGF and its receptors, we have shown
previously that the VEGFR–Neuropilin interactions explain the observed differential effects of VEGF isoforms on VEGF
signaling in vitro, and demonstrated potent VEGF inhibition by an antibody to Neuropilin-1 that does not block ligand
binding but blocks subsequent receptor coupling. In the present study, we extend that computational model to
simulation of in vivo VEGF transport and binding, and predict the in vivo efficacy of several Neuropilin-targeted
therapies in inhibiting VEGF signaling: (a) blocking Neuropilin-1 expression; (b) blocking VEGF binding to Neuropilin-1;
(c) blocking Neuropilin–VEGFR coupling. The model predicts that blockade of Neuropilin–VEGFR coupling is
significantly more effective than other approaches in decreasing VEGF–VEGFR2 signaling. In addition, tumor types
with different receptor expression levels respond differently to each of these treatments. In designing human
therapeutics, the mechanism of attacking the target plays a significant role in the outcome: of the strategies tested
here, drugs with similar properties to the Neuropilin-1 antibody are predicted to be most effective. The tumor type and
the microenvironment of the target tissue are also significant in determining therapeutic efficacy of each of the
treatments studied.
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Introduction
Angiogenesis (neovascularization), the growth of new blood
microvessels from preexisting microvasculature, is a critical
physiological process for the growth of developing organs
and during wound healing, ovulation, and pregnancy.
Coronary or peripheral ischemia may be relieved by inducing
angiogenesis [1,2], while diseases of hypervascularization,
such as cancer or diabetic retinopathy, are targets of anti-
angiogenic drugs [3,4]. Neuronal expression of angiogenic
receptors [5,6] suggests that this work may also be relevant to
the development nervous system. Our goal is to propose
effective targeted therapies using anatomically accurate and
molecularly detailed computational models of the growth
factors and receptors involved in angiogenesis. In this study,
we predict that three methods of targeting the same molecule
(Neuropilin-1) result in distinct therapeutic outcomes, and
that one of these methods is more effective (in terms of
decreasing VEGF–VEGFR2 signaling for a deﬁned period of
time following treatment) than the others. Thus, identiﬁca-
tion of a therapeutic target must be followed by rational
design of the targeting molecule to obtain characteristics that
maximize the therapeutic potential. In addition, the micro-
environment in which the drug is to act—for example, the
expression level of receptors in the tissue—is a critical factor
in the impact of the therapy.
Vascular endothelial growth factor (VEGF) is a family of
secreted glycoproteins and critical regulators of angiogenesis
[7,8]. In vitro, VEGF increases endothelial cell survival,
proliferation, and migration. In vivo, it increases vascular
permeability, activates endothelial cells, and acts as a
chemoattractant for nascent vessel sprouts. Multiple splice
isoforms of VEGF exist; the two most abundant in the human
are VEGF121 and VEGF165. Both isoforms bind to the VEGF
receptor tyrosine kinases (VEGFRs) to induce signals.
VEGF165 also interacts with nonsignaling Neuropilin co-
receptors and with proteoglycans of the extracellular matrix
(ECM) [9,10] (Figure 1). The binding sites on VEGF165 for
VEGFR2 and Neuropilin-1 are nonoverlapping, so VEGF165
may bind both simultaneously [9]. There are thus two parallel
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directly to VEGFR2; and binding to Neuropilin-1, which
presents VEGF to VEGFR2 (coupling the two receptors
together). VEGF121 can only form VEGFR2 complexes
directly [10]. The VEGF165–Neuropilin interaction is thus of
particular value as a therapeutic target because VEGF165 is
the isoform of VEGF that has been identiﬁed as inducing
pathological angiogenesis [11,12]: aberrant angiogenic signal-
ing may be targeted while allowing the normal levels of
physiological VEGF signaling to continue.
In previous work [9,13], we developed computational
models of VEGF interactions with endothelial cell receptors
in vitro, and incorporated previously published experimental
data to estimate the kinetic rate of VEGFR2-Neuropilin
coupling by VEGF165. We showed that VEGFR2–Neuropilin
coupling is sufﬁcient to account for the observed differential
effects of VEGF isoforms on multiple cell types and that our
model reproduces the distinct VEGF binding and signaling
effects on each of these cell types [10,14–16]. In addition, we
used the model to distinguish between alternate hypotheses
of molecular mechanisms of action and demonstrated that
the Neuropilin-1 antibody under investigation acts by block-
ing VEGFR–Neuropilin coupling, not by blocking VEGF–
Neuropilin binding. Here, we extend that validated model of
the molecular interactions of the VEGF family and its
receptors to predict the in vivo behavior of the system by
including the ECM and basement membranes, as well as
multiple cell types (tumor cells and endothelial cells) and
geometrical parameters characteristic of the tissue.
Three methods for targeting the VEGF165–Neuropilin
interaction are modeled here. First, a blockade of Neuro-
pilin-1 expression may be induced by use of siRNA or other
methods to prevent the synthesis of the protein in the cells.
Second, a protein that occupies the VEGF binding site on
Neuropilin-1 can compete with VEGF165 for binding to that
receptor. An example is a fragment of the placental growth
factor isoform PlGF2. Full-length PlGF2 (a VEGF homolog)
binds Neuropilin-1 and VEGFR1 (but not VEGFR2) [17]. The
fragment, denoted PlGF2D here, contains only the Neuro-
pilin-1 binding site and does not bind to VEGFR1. This
protein has been used to block VEGF binding to Neuropilin
in vitro [14,17]. An alternative would be a Neuropilin-binding
fragment of VEGF165 itself [18,19]. Third, we may block the
interaction between Neuropilins and the VEGFRs, preventing
Figure 1. Schematics of VEGF Transport in Tumors, VEGF Receptor Binding, and Therapeutic Strategies
(A) Schematic of the in vivo model. Parenchymal cells secrete VEGF; VEGF121 is freely diffusible, but VEGF165 can be sequestered by proteoglycans in the
ECM (light gray) and the basement membranes (dark gray). The isoforms bind to VEGF receptors on the endothelial cells.
(B) VEGF isoforms bind to VEGFR2 that transduces the angiogenic signal intracellularly. VEGF121 does not bind Neuropilin-1; VEGF165 may bind both
VEGFR2 and Neuropilin-1 simultaneously. Thus there are two pathways for the binding of VEGF165 to the signaling VEGFR2 receptor: first by binding
directly, and second by binding Neuropilin-1 and then diffusing laterally on the cell surface to couple to VEGFR2. VEGFR1, which modulates the
signaling of VEGFR2, binds both isoforms of VEGF. VEGFR1 also binds directly to Neuropilin-1. This complex is permissive for VEGF121–VEGFR1 binding
but not VEGF165–VEGFR1; thus, high levels of Neuropilin-1 displace VEGF165 from VEGFR1, making it available for VEGFR2 binding. Only VEGF165 binds
directly to the ECM binding site (represented by GAG chains).
(C) By targeting Neuropilin-1, we can target specifically VEGF165-induced signaling. Three methods for targeting Neuropilin-1 are analyzed here:
blockade of Neuropilin-1 expression (e.g., using siRNA); blockade of VEGF–Neuropilin binding (e.g., using a fragment of placental growth factor to
occupy the binding site); and blockade of VEGFR–Neuropilin coupling (e.g., using an antibody for Neuropilin-1 that does not interfere with VEGF–
Neuropilin binding).
doi:10.1371/journal.pcbi.0020180.g001
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Synopsis
Neuropilin is a co-receptor for some of the isoforms of the vascular
endothelial growth factor (VEGF) family. The presence of Neuropilin
on endothelial or other cells increases binding of these isoforms to
their signaling receptor VEGFR2, thus increasing pro-angiogenesis
signaling and stimulating vascular growth. Neuropilin is thus a
suitable target for anti-angiogenesis therapy, which holds promise
for the treatment of vasculature-dependent diseases such as cancer
and diabetic retinopathy. In this study, Mac Gabhann and Popel
perform computational simulations of VEGF transport in breast
cancer, using a previously validated model of VEGF–VEGF receptor
interactions, as well as geometrical information on the tumor itself—
tumor cells, vasculature, and extracellular matrix. Three different
molecular therapies targeting Neuropilin are tested in silico, and the
simulations predict that one of these therapies will be effective at
reducing VEGFR2 signaling in certain types (or subtypes) of tumors,
while the others will not. Thus, we demonstrate that identification of
a target molecule is not sufficient; different therapeutic strategies
targeting the same molecule may result in different outcomes.
Therapeutic Targeting of Neuropilin-1the presentation of VEGF165 to the signaling receptor, but
permitting Neuropilin to sequester that isoform. This may be
done using a Neuropilin-1 antibody [20–23] that we have
previously characterized as permitting VEGF binding to
Neuropilin-1, but blocking the subsequent VEGFR coupling
[9]. Each of these three strategies has been demonstrated to
inhibit VEGF signaling in in vitro assays [14,15,17,24]; here we
predict their in vivo efﬁcacy.
This is the ﬁrst computational model to our knowledge to
include the interactions of the VEGF family and their
receptors explicitly and in biophysical detail. The model
includes the kinetics of all ligand–receptor interactions,
which allows us to examine both short-term and long-term
behavior of the system. All the parameters for the model have
been obtained from previously published experimental data.
Analysis of characteristic parameters shows that the kinetics
of VEGF interactions are slower than the diffusion process, so
diffusion is assumed to be fast, and we construct a
compartmental model (i.e., spatial gradients of VEGF are
not considered) with parenchymal cells secreting VEGF into
the interstitial space and VEGF binding to receptors on the
endothelial cell surface (Figure 1A).
The geometrical parameters of the tissue under inves-
tigation here (breast tumor) are also incorporated into the
model: interstitial space, tumor cell volume and surface area,
microvessel volume and surface area. Changes to these
parameters would result in changes to the kinetic parameters
and concentrations in the model. The results presented here
are therefore tissue-speciﬁc, but the model may be applied to
other tissues.
VEGFR2 is the primary signaling receptor for VEGF, and
we ﬁrst analyze the results of the model for a tissue in which
the endothelial cells express VEGFR2 and Neuropilin-1, but
not VEGFR1; the effect of VEGFR1 is considered later.
Initially, the system is in a steady state, as VEGF is secreted by
the parenchymal cells and internalized by the endothelial
cells, resulting in a ﬂux through the interstitial space and the
ECM (Figure 1A). One of three treatments is initiated at time
zero and the time course of VEGF binding followed for 48
hours. VEGF–VEGFR2 and VEGF–VEGFR1 binding are taken
as a surrogate for VEGF signaling.
Results
Development of the Computational Model
Computational model. We constructed a computational
model of VEGF transport and interactions with its receptors
in tumor tissue in vivo. The interstitial space between the
tumor cells and the blood vessels is divided into three regions:
the ECM, and the two basement membranes surrounding the
tumor cells and the blood vessel endothelial cells (TBM and
EBM, respectively). VEGF is secreted by the tumor cells and
binds to cell surface receptors on the endothelial cells. In the
case of VEGF165, it may also be sequestered by VEGF binding
sites in the ECM and basement membranes. This sequestered
VEGF can serve as a reservoir to buffer dynamic changes in
free VEGF concentration. The binding interactions between
VEGF121, VEGF165, and the receptors VEGFR1, VEGFR2, and
Neuropilin-1 are shown in Figure 2A and 2B. We assume that
the concentration of free (unbound) VEGF is uniform across
the interstitial space. The Damkohler number (the ratio of
diffusion time to reaction time) is signiﬁcantly less than one
for this tissue, indicating that diffusion is signiﬁcantly faster
than the kinetics of binding to and unbinding from ECM
glycosaminoglycan (GAG) chains or cell surface receptors.
The possible formation of diffusion-limited VEGF gradients
will therefore not be studied here; instead, our model
represents average VEGF in the interstitium, and average
receptor binding on the cell surface. Spatial variability in
binding due to gradient formation may also be important for
angiogenic signaling in vivo [25,26], but is not dealt with here;
the variability would likely impact each of the three
therapeutic strategies under consideration similarly. The
mean concentration values in spatial models are predicted
to be the same as the concentration in spatially averaged
models such as this [25,27]. Although we do not model
gradients here, there are major spatial features—basement
membrane, and cell surfaces—that have a signiﬁcant impact
on VEGF distribution and VEGF receptor signaling. Thus the
system is described by a set of coupled nonlinear ordinary
differential equations. For interstitial proteins, these equa-
tions are as follows:
d½V121 =dt ¼ qV121;T   kon;VR1½V121  ½ R1 þkoff;VR1½V121R1 
  kon;VR2½V121  ½ R2 þkoff;VR2½V121R2 
  kon;VR1½V121  ½ R1N1 þkoff;VR1½V121R1N1 
d½V165 =dt ¼ q165;T   kon;VM½V165  ½ MECM 
þ koff;VM½V165MECM  kon;VM½V165  ½ MEBM 
þ koff;VM½V165MEBM  kon;VM½V165  ½ MTBM 
þ koff;VM½V165MTBM  kon;VR1½V165  ½ R1 
þ koff;VR1½V165R1  kon;VR2½V165  ½ R2 
þ koff;VR2½V165R2  kon;VN1½V165  ½ N1 
þ koff;VN1½V165N1 
d½MECM =dt ¼  kon;V165;M½V165  ½ MECM þkoff;V165;M½V165MECM 
d½MEBM =dt ¼  kon;V165;M½V165  ½ MEBM þkoff;V165;M½V165MEBM 
d½MTBM =dt ¼  kon;V165;M½V165  ½ MTBM þkoff;V165;M½V165MTBM 
d½V165MECM =dt ¼ kon;VM½V165  ½ MECM  koff;VM½V165MECM 
d½V165MEBM =dt ¼ kon;VM½V165  ½ MEBM  koff;VM½V165MEBM 
d½V165MTBM =dt ¼ kon;VM½V165  ½ MTBM  koff;VM½V165MTBM 
Here [V] represents the concentration of a VEGF isoform; [M]
the concentration of VEGF binding sites in the ECM, EBM, or
TBM; [R] the density of cell surface receptor tyrosine kinases;
[N] the density of cell surface Neuropilin; qV,T is the secretion
rate of VEGF from the tumor cells, and kon and koff are the
kinetic rates of binding and unbinding, respectively.
Although we note VEGF as secreted from the tumor cells,
VEGF secreted from other sources, e.g., endothelial cells
themselves, if signiﬁcant, could be included in the same term
by adding all the sources of VEGF together. In addition,
VEGF secretion is assumed constant; no feedback mechanism
is included for increasing or decreasing secretion in response
to VEGF receptor signaling. Such a mechanism could serve to
blunt the response of each of the inhibitors. For cell surface
receptors, we have the following equations:
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Therapeutic Targeting of Neuropilin-1d½R1 =dt ¼ sR1   kint;R1½R1  kon;VR1½V121  ½ R1 
þ koff;VR1½V121R1  kon;VR1½V165  ½ R1 
þ koff;VR1½V165R1  kc;R1N1½R1  ½ N1 þkdissoc½R1N1 
d½R2 =dt ¼ sR2   kint;R2½R2  kon;VR2½V121  ½ R2 
þ koff;VR2½V121R2  kon;VR2½V165  ½ R2 
þ koff;VR2½V165R2  kc;R2;VN1½V165N1  ½ R2 
þ koff;VR2½R2V165N1 
d½N1 =dt ¼ sN1   kint;N1½N1  kon;VN1½V165  ½ N1 
þ koff;VN1½V165N1  kc;VR2;N1½V165R2  ½ N1 
þ koff;VN1½R2V165N1 
d½V121R1 =dt ¼  kint;VR1½V121R1 þkon;VR1½V121  ½ R1 
  koff;VR1½V121R1  kc;R1N1½V121R1  ½ N1 
þ kdissoc½V121R1N1 
d½V121R2 =dt ¼  kint;VR2½V121R2 þkon;VR2½V121  ½ R2 
  koff;VR2½V121R2 
d½V165R1 =dt ¼  kint;VR1½V165R1 þkon;VR1½V165  ½ R1 
  koff;VR1½V165R1 
d½V165R2 =dt ¼  kint;VR2½V165R2 þkon;VR2½V165  ½ R2 
  koff;VR2½V165R2  kc;VR2;N1½V165R2  ½ N1 
þ koff;VN1½R2V165N1 
d½V165N1 =dt ¼  kint;VN1½V165N1 þkon;VN1½V165  ½ N1 
  koff;VN1½V165N1  kc;R2;VN1½V165N1  ½ R2 
þ koff;VR2½R2V165N1 
d½R2V165N1 =dt ¼  kint;VR2½R2V165N1 þkc;VR2;N1½V165R2  ½ N1 
  koff;VN1½R2V165N1 þkc;R2;VN1½V165N1  ½ R2 
  koff;VR2½R2V165N1 
d½V121R1N1 =dt ¼  kint;VR1½V121R1N1 þkc;R1N1½V121R1  ½ N1 
  kdissoc½V121R1N1 þkon;VR1½V121  ½ R1N1 
  koff;VR1½V121R1N1 
d½R1N1 =dt ¼  kint;R1½R1N1 þkc;R1N1½R1  ½ N1  kdissoc½R1N1 
  kon;VR1½V121  ½ R1N1 þkoff;VR1½V121R1N1 
where [VR] is the concentration of VEGF-bound receptor;
[VN] is the concentration of VEGF-bound Neuropilin; [RVN]
is the concentration of the VEGF-coupled VEGFR–Neuro-
pilin complex; kc is the coupling rate of Neuropilin-bound or
VEGFR-bound VEGF to a second receptor; sR is the insertion
rate of new receptors into the membrane, and kint is the
internalization rate of receptors.
Thesignalingligand–receptorcomplexesformedbyVEGF121,
VEGF165, and theirreceptors are shown inFigure 1, and the full
systemofinteractionsisshowninFigure2Aand2B.Thecoupled
set of ordinary differential equations is solved for appropriate
values of the parameters (below) to ﬁnd the initial steady state
concentrations of all molecular species. Then, an intervention
Figure 2. Interactions between VEGF121, VEGF165, and Their Cell Surface Receptors VEGFR1, VEGFR2, and Neuropilin-1, and Interstitial GAG Binding Sites
(A) VEGF121 binds to VEGFR2 but not Neuropilin-1. VEGF165 binds both receptors as well as GAG chains in the interstitial space. VEGF165 bound to
Neuropilin-1 can diffuse laterally on the cell membrane and bind VEGFR2 (and vice versa), coupling these receptors together, even though the receptors
themselves do not interact.
(B) VEGF121 and VEGF165 both bind VEGFR1. Neuropilin-1 and VEGFR1 interact directly, forming a complex that is permissive for VEGF121 binding but not
VEGF165.
(C) Inhibition of Neuropilin-1 expression results in a decrease in the insertion rate of Neuropilin receptors into the cell membrane (sN).
(D) PlGF2D, a fragment of placental growth factor, competes with VEGF165 for the binding site on Neuropilin-1.
(E) An antibody to Neuropilin-1 that does not interfere with VEGF165 binding can block the coupling of VEGF165–Neuropilin to VEGFR2, resulting in
sequestration of VEGF on nonsignaling Neuropilin.
doi:10.1371/journal.pcbi.0020180.g002
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Therapeutic Targeting of Neuropilin-1takes place and the system of equations is simulated to ﬁnd the
response for 48 hours following the intervention.
Therapeutic interventions. One of three Neuropilin-target-
ing therapies is used and the system is observed for 48 hours.
The ﬁrst modiﬁcation of Neuropilin expression is a change in
the value of sN, the insertion rate of Neuropilin into the
membrane (Figure 2C). No other parameters are affected, and
no new molecular species, interactions, or equations are
required. The second and third interventions require the
addition of two new molecular species: PlGF2 (or a fragment
thereof) and an antibody to Neuropilin (AbNRP)o ra
molecule-blocking Neuropilin–VEGFR2 coupling in a similar
fashion, and their associated interactions.
As described in the introduction, PlGF2D is a fragment of
placental growth factor that binds only to the VEGF165
binding sites of Neuropilin (Figure 2D). This is the only added
interaction required for simulation of this therapy. The
addition of this interaction requires two additional model
equations (for PlGF2D and the PlGF2D–Neuropilin complex):
d½P2D =dt ¼  kon;PN1½P2D  ½ N1 þkoff;PN1½P2DN1 
d½P2DN1 =dt ¼  kint;PN1½P2DN1 þkon;PN1½P2D  ½ N1 
  koff;VN1½P2DN1 
It also requires modiﬁcations to the equation governing
Neuropilin concentration:
d½N1 =dt ¼  kint;N1½N1  kon;VN1½V165  ½ N1 þkoff;VN1½V165N1 
  kon;PN1½P2D  ½ N1 þkoff;PN1½P2DN1 
  kc;VR2;N1½V165R2  ½ N1 þkoff;VN1½R2V165N1 
The kinetics of the interaction were obtained from simu-
lations of in vitro competition experiments [9,14]. We assume
that this protein does not bind to the ECM (although the full-
length PlGF2 may bind). ECM binding would further reduce
its predicted efﬁcacy.
The antibody to Neuropilin being investigated here does
not affect VEGF binding to Neuropilin [9,20–23]. It binds to a
different domain of Neuropilin and allows VEGF binding to
proceed; however, it then prevents the coupling of VEGFR2
to the VEGF–Neuropilin complex (Figure 2E). The binding of
the antibody to Neuropilin, as well as the binding of VEGF165
to the antibody-bound receptor, are added to the interactions
in the model. New equations for the antibody and the
complexes it forms are added to the model:
d½AbNRP =dt ¼  kon;AbN1½AbNRP  ½ N1 þkoff;AbN1½AbNRPN1 
  kon;AbN1½AbNRP  ½ V165N1 
þ koff;AbN1½V165N1AbNRP 
d½AbNRPN1 =dt ¼  kint;VN1½AbNRPN1 þkon;AbN1½AbNRP  ½ N1 
  koff;AbN1½AbNRPN1 
  kon;VN1½V165  ½ AbNRPN1 
þ koff;VN1½V165N1AbNRP 
d½V165N1AbNRP =dt ¼  kint;VN1½V165N1AbNRP 
þ kon;AbN1½AbNRP  ½ V165N1 
  koff;AbN1½V165N1AbNRP 
þ kon;VN1½V165  ½ AbNRPN1 
  koff;VN1½V165N1AbNRP 
In addition, several equations in the model are modiﬁed to
include the effects of the antibody:
d½V165 =dt ¼ q165;T   kon;VM½V165  ½ MECM þkoff;VM½V165MECM 
  kon;VM½V165  ½ MEBM þkoff;VM½V165MEBM 
  kon;VM½V165  ½ MTBM þkoff;VM½V165MTBM 
  kon;VR1½V165  ½ R1 þkoff;VR1½V165R1 
  kon;VR2½V165  ½ R2 þkoff;VR2½V165R2 
  kon;VN1½V165  ½ N1 þkoff;VN1½V165N1 
  kon;VN1½V165  ½ AbNRPN1 þkoff;VN1½V165N1AbNRP 
Table 1. Microgeometrical Parameters for Breast Cancer
Tissue Feature Parameter Value Unit Reference
Cancer cells Tumor cells external diameter 17 lm [28]
Volume of one cell 2,572 lm
3 See text
Surface area of one cell 997 lm
2 See text
Microvessels Average lumenal diameter 10.3 lm [29,30]
Endothelial cell thickness 0.5 lm Estimated
Average external diameter 11.3 lm Calculated
Cross-sectional area of one vessel 100.3 lm
2 Calculated
Perimeter of one vessel 35.5 lm See text
Volume fractions Interstitial space 58% cm
3/cm
3 tissue [33,34]
Cancer cells 39.6% cm
3/cm
3 tissue Calculated
Microvessels 2.4% cm
3/cm
3 tissue See text
Of which intravascular space 2% See text
Surface areas Tumor cells 1,534 cm
2/cm
3 tissue Calculated
Microvessels 105 cm
2/cm
3 tissue Calculated
Basement membranes TBM thickness 30 nm See text
TBM volume 0.42% cm
3/cm
3 tissue Calculated
0.73% cm
3/cm
3 interstitium Calculated
EBM thickness 50 nm See text
EBM volume 0.04% cm
3/cm
3 tissue Calculated
0.07% cm
3/cm
3 interstitium Calculated
ECM volume 57.5% cm
3/cm
3 tissue Calculated
99.2% cm
3/cm
3 interstitium Calculated
doi:10.1371/journal.pcbi.0020180.t001
PLoS Computational Biology | www.ploscompbiol.org December 2006 | Volume 2 | Issue 12 | e180 1653
Therapeutic Targeting of Neuropilin-1d½N1 =dt ¼  kint;N1½N1  kon;VN1½V165  ½ N1 þkoff;VN1½V165N1 
  kc;VR2;N1½V165R2  ½ N1 þkoff;VN1½R2V165N1 
  kon;AbN1½AbNRP  ½ N1 þkoff;AbN1½AbNRPN1 
d½V165N1 =dt ¼  kint;VN1½V165N1 þkon;VN1½V165  ½ N1 
  koff;VN1½V165N1  kc;R2;VN1½V165N1  ½ R2 
þ koff;VR2½R2V165N1  kon;AbN1½AbNRP  ½ V165N1 
þ koff;AbN1½V165N1AbNRP 
Parameters. The parameters required for simulation of this
model fall into three categories: geometric, kinetic rates, and
initial concentrations; they are given in Tables 1–3.
Geometry. The model is applicable to any solid tumor. To
be speciﬁc, in this study we use the geometric parameters
typical for breast cancer as summarized in Table 1. The tumor
cells are assumed to have the same volume as the MCF7 breast
tumor cell line, which have a mean diameter of 17 lm [28], for
an equivalent spherical volume of 2,572 lm
3. A sphere of this
volume would have a surface area of 908 lm
2, but tumor cells
are not spherical. We assume a dodecahedral cell of the same
volume, which has a surface area of 997 lm
2 (10% increase
over the sphere). The average diameter of capillaries in breast
cancer has been measured as 10.3 lm (lumenal diameter)
[29,30]. Assuming an endothelial cell thickness of 0.5 lm, this
would yield a cylindrical cross-sectional area of 100 lm
2 and
an outer perimeter of 35.5 lm. However, microvessels are not
cylindrical, and to ﬁnd the true perimeter we used a
Table 2. Kinetic Parameters of VEGF System
Reaction Parameter Measured Parameter Tissue Model
Value Unit Value Unit
VEGF binding to VEGFR1 kon 31 0
7 M
 1 s
 1 5.2 10
 2 (pmol/cm
3 tissue)
 1 s
 1
koff 10
 3 s
 1
Kd 33 pM 1.9 10
2 pmol/cm
3 tissue
VEGF binding to VEGFR2 kon 10
7 M
 1 s
 1 1.7 10
 2 (pmol/cm
3 tissue)
 1 s
 1
koff 10
 3 s
 1
Kd 100 pM 5.8 10
 2 pmol/cm
3 tissue
VEGF165 binding to NRP1 kon 3.2 10
6 M
 1 s
 1 5.5 10
 3 (pmol/cm
3 tissue)
 1 s
 1
koff 10
 3 s
 1
Kd 312 pM 1.8 10
 1 pmol/cm
3 tissue
VEGF165 binding to ECM kon 4.2 10
5 M
 1 s
 1 7.2 10
 4 (pmol/cm
3 tissue)
 1 s
 1
koff 10
 2 s
 1
Kd 24 nM 13.8 pmol/cm
3 tissue
Coupling of NRP1 and VEGFR2 kcVR2,N 3.1 10
13 (mol/cm
2)
 1 s
 1 2.9 10
 1 (pmol/cm
3 tissue)
 1 s
 1
koffVR2,N 10
 3 s
 1
kcVN,R2 10
14 (mol/cm
2)
 1 s
 1 9.5 10
 1 (pmol/cm
3 tissue)
 1 s
 1
koffVN,R2 10
 3 s
 1
VEGFR1 coupling to NRP1 kcR1,N 10
14 (mol/cm
2)
 1 s
 1 9.5 10
 1 (pmol/cm
3 tissue)
 1 s
 1
koffR1,N 10
 2 s
 1
VEGFR internalization kint 2.8 10
 4 s
 1
The conversion from in vitro parameters to tissue parameters is based on the geometrical parameters (Table 1): 5.8 10
8 (pmol/cm
3 tissue)/(mol/liter of interstitial space) and 1.05 10
14
(pmol/cm
3 tissue)/(mol/cm
2 EC). The effect of tissue geometry is thus included in the model through the kinetic parameters (this table) and concentrations (see Table 3).
doi:10.1371/journal.pcbi.0020180.t002
Table 3. VEGF Concentration and VEGFR Density
Category Parameter Measured Parameter Tissue Model
Value Unit Value Unit
Free VEGF concentration Breast cancer [42,43] 0.5–1.5 pM 3–9 10
 4 pmol/cm
3 tissue
Total tumor VEGF Breast cancer [42] 13 pg/mg tumor 0.3 pmol/cm
3 tissue
VEGFR density VEGFR1 10
2–10
5 Number/cell 1.7 10
 3–1.7 10
0 pmol/cm
3 tissue
VEGFR2 10
4 Number/cell 1.7 10
 1 pmol/cm
3 tissue
Neuropilin-1 10
3–10
6 Number/cell 1.7 10
 2–1.7 10
1 pmol/cm
3 tissue
ECM binding site density ECM 0.75 lM 432 pmol/cm
3 tissue
EBM 13 lM 6 pmol/cm
3 tissue
TBM 13 lM 55 pmol/cm
3 tissue
The conversion of receptor densities to tissue concentrations is based on the relationship mentioned in Table 2, and the surface area of an endothelial cell, 1,000 lm
2. VEGF concentration
is normalized based on the entire interstitial space, since it diffuses throughout: 5.8 10
8 (pmol/cm
3 tissue)/(mol/liter of interstitial space). VEGF binding sites in the ECM and BMs are based
on those volumes: 5.75 10
8 (pmol/cm
3 tissue)/(mol/liter of ECM), 4.3 10
5 (pmol/cm
3 tissue)/(mol/liter of EBM), 4.2 10
6 (pmol/cm
3 tissue)/(mol/liter of TBM). The effect of tissue geometry is
thus included in the model through both the concentrations (this table) and the kinetic parameters (see Table 2).
doi:10.1371/journal.pcbi.0020180.t003
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Therapeutic Targeting of Neuropilin-1relationship between total perimeter and total cross-sectional
area measured in breast cancer. The increase in perimeter
over that predicted by cylinders from the area data is 23%
[31,32], for a capillary perimeter of 43.7 lm.
The average extracellular ﬂuid volume in breast tumors has
been measured from 51%–63% [33,34], although the range of
individual measurements is even wider. We assume a value of
60%, which is divided into interstitial space and vascular
Figure 3. VEGF Binding to VEGFR2 In Vivo Is Inhibited by Targeting Neuropilin-1
(A–C) The time course of VEGF–VEGFR2 complex formation on the endothelial cells following each of the three treatments. For blocking VEGF–
Neuropilin-1 binding (B) and VEGFR–Neuropilin-1 coupling (C), this figure represents bolus intratissue protein delivery at time 0. For Neuropilin-1
expression blockade, insertion of Neuropilin-1 into the membrane decreases to the indicated level at time 0. The VEGF121–VEGFR2 binding curve is
indistinguishable from the no-treatment line in each case. The tumor modeledhere expresses 10,000 VEGFR2and 100,000 Neuropilin per endothelial cell.
(D–F) Free (unbound) VEGF concentration in the interstitial space. *VEGF121 secreted at the same rate as VEGF165.
(G–I) The concentration of VEGF inhibitor in the interstitial space, or density of Neuropilin, on the blood vessel endothelial cell surface.
doi:10.1371/journal.pcbi.0020180.g003
Figure 4. Average VEGF–VEGFR2 Signaling Inhibition
TheaverageinhibitionofVEGF–VEGFR2complexformationoverthe48hoursfollowingblockadeofNeuropilin-1expression(A),orbolusintratissueprotein
delivery(B)ofcompetitivebindinginhibitororVEGFR–Neuropilin-1couplingblocker.Endothelialcellsexpressing10,000VEGFR2and100,000Neuropilin-1.
doi:10.1371/journal.pcbi.0020180.g004
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contained in the tumor cells themselves, as well as in the
endothelial cells of the blood vessels.
The vascular density appears to range widely for breast
cancer, with 100–500 capillaries/mm
2 cross-sectional area of
tissue measured in different tumor samples [35]. Many studies
of vascular density in breast cancer have been performed (see
[36] for a comprehensive list and review), and typical average
values are 100–250 capillaries/mm
2. For the capillary dimen-
sions described above, a capillary density of 235 capillaries/
mm
2 gives a vascular volume of 2% cm
3/cm
3 tissue. This is
lower than the microvascular volume of 5% (even allowing
for volume of the endothelial cells) found in studies of
vascular volume [37,38]. This volume would require a
Figure 5. Tissue Expressing High VEGFR1 Levels Responds Differently to Treatment
(A–C) Formation of VEGF–VEGFR2 complexes over time following anti-Neuropilin treatment, for a tumor expressing 10,000 VEGFR1 per endothelial cell
in addition to the VEGFR2 and Neuropilin-1 expression of Figures 3 and 4.
(D–F) VEGF–VEGFR1 complex formation.
(G–I) Free (unbound) interstitial VEGF concentration. *VEGF121 secreted at the same rate as VEGF165.
doi:10.1371/journal.pcbi.0020180.g005
Figure 6. Average VEGF–VEGFR2 Signaling Inhibition over the 48 Hours Following Treatment
Endothelial cells expressing 10,000 VEGFR1, 10,000 VEGFR2, and 100,000 Neuropilin-1.
doi:10.1371/journal.pcbi.0020180.g006
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2) for
the average capillary size noted above. The reason for the
discrepancy may be the inclusion in that study of larger
microvessels, or the differences between the types of cancer
studied. We performed most of the simulations (Figures 3–7)
using the 2% vascular space, but also performed simulations
for the larger vascular volume and included those for
comparison (Figures 8 and 9).
The 2% vascular volume gives us an interstitial volume of
58% cm
3/cm
3, and having ﬁxed the total vascular volume and
the size of each vessel, the volume taken up by the endothelial
cells of the microvessels is determined to be 0.4% cm
3/cm
3
based on 0.5 lm thickness. The remaining tissue volume
(39.6%) is occupied by the cancer cells.
From the relative volumes of each of the extracellular
regions, and the surface areas of the vessels and tumor cells,
we can calculate the total surface area of all vessels and tumor
cells per unit volume of tissue. For the above parameters, they
are 105 cm
2 endothelial cell surface / cm
3 tissue and 1,534 cm
2
tumor cell surface / cm
3 tissue.
Last, both the vessels and the tumor cells have associated
basement membranes. The thickness of these was not
available for breast cancer, and we have assumed thickness
of 50 nm and 30 nm, which are within the range of
thicknesses of basement membranes observed in other tissues
[39,40], but relatively thin, in consideration of the high
density of proteases present in tumors. These thicknesses are
used to calculate the volumes of each type of basement
membrane in the tumor tissue.
Kinetics. The kinetic rates for VEGF isoform binding to
and unbinding from VEGF receptors and Neuropilins are
based on experimental measurements and are similar to
those used in previous models [9], and are summarized in
Table 2. The ECM binding sites for VEGF are a diverse group
of protein and proteoglycan with different afﬁnities. An
effective binding afﬁnity is used for the ensemble of sites.
VEGF binding afﬁnity to the GAG chains on the proteogly-
cans of the ECM chains is of a similar order to that of bFGF,
and therefore we use similar binding site density and afﬁnity
[41]. The afﬁnity of the PlGF2D fragment for Neuropilin is
assumed to be the same as VEGF for Neuropilin. The afﬁnity
of the anti-Neuropilin antibody for Neuropilin has not been
measured and is assumed to be 0.1 nM, typical of other
antibodies.
Concentrations. The initial concentration of unbound
VEGF has been determined by microdialysis of breast tumors
to be in the range 20–70 pg/ml, or 0.5–1.5 pM [42,43]. This is
approximately 10-fold higher than normal breast tissue [44].
We begin all simulations at a steady state with a free VEGF
concentration of 1 pM. Although VEGFR1, VEGFR2, and
Neuropilin all have been identiﬁed as being expressed on the
endothelial cells of the vasculature, no quantitative estimate
of the receptor density in breast cancer has been published.
As a result, we will examine several expression levels of these
receptors—starting with estimates from other tissues—to
estimate the effect of receptor density on the efﬁcacy of the
therapies. For Figures 3, 4, 8, and 9, 10,000 VEGFR2 and
100,000 NRP1 are expressed on each endothelial cell. For
Figures 5 and 6, 10,000 VEGFR1 are added. In Figure 7, the
sensitivity of the results to VEGFR expression is explored.
Geometrical conversion of the parameters. For the set of
ordinary differential equations above, concentrations are
expressed in per-tissue-volume units. That is, interstitial
concentrations are expressed as pmol/(cm
3 tissue) rather than
pM; pM in this case would be equivalent to pmol/(liter of
interstitium). Surface concentrations are similarly expressed
as pmol/(cm
3 tissue) rather than per-surface-area units such
as molecules/cell or pmol/(cm
2 cell surface area). All of these
Figure 7. Tissue Specificity of Neuropilin-Targeted Inhibition of VEGF Signaling
Tissues that express low levels of Neuropilin-1 are insensitive to all Neuropilin-targeting treatments. The inhibition of VEGF–VEGFR2 signaling is directly
proportional to Neuropilin-1 density (A–C), except at very high Neuropilin levels, which can overcome the inhibition. Tissues that express intermediate
and high levels of Neuropilin-1 are further distinguished by the level of expression of VEGFR1. Blocking VEGFR–Neuropilin coupling is the most effective
treatment to reduce VEGF–VEGFR2 signaling for tissues with any VEGFR1 expression level. However, in high VEGFR1 tissues, the other treatments are
also quite effective. All three treatments significantly induce VEGF–VEGFR1 complex formation (D–F). The circles in each figure denote the conditions for
Figures 3 and 4 (left, VEGFR1 actually zero in simulations) and Figures 5 and 6 (right) to compare the efficacy of the treatments for different tumors. The
results shown are for a Neuropilin-1 expression knockdown to 1%, for 1 lM PlGF2D, and 1 lMA b NRP.
doi:10.1371/journal.pcbi.0020180.g007
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geometrical parameters as described in the legend of Table 3.
For the equations to hold, the units of the parameters used
in the equations must also be changed to be consistent, e.g.,
the units of kon are converted from (M
 1 s
 1) to (pmol
 1 (cm
3
tissue) s
 1) using the fractional volume of the interstitial
space. This is explicitly performed in Table 2. Note that the
tumor cell surface area, the vasculature surface area, and the
Figure 8. VEGF Signaling Inhibition Is Effective for a Shorter Period of Time for a Tissue with a Higher Microvascular Density
(A–C) VEGF–VEGFR2 complex formation on the endothelial cells following each of the three treatments. The tumor modeled here expresses 10,000
VEGFR2 and 100,000 Neuropilin per endothelial cell. Gray lines represent the case of 2% vascular volume, as depicted in Figure 3; the black lines
represent 4.2% vascular volume. Note that while the 10
3/cell, pM, and nM scales apply to both the gray and black lines, the pmol/L tissue scales apply
only to the black lines; the normalization is different for the gray lines (see Figure 3 for the correct scales).
(D–F) Free (unbound) VEGF concentration in the interstitial space. *VEGF121 secreted at the same rate as VEGF165.
(G–I) The concentration of VEGF inhibitor in the interstitial space, or density of Neuropilin on the blood vessel endothelial cell surface.
doi:10.1371/journal.pcbi.0020180.g008
Figure 9. Average VEGF Signaling for the 48 Hours Following Treatment Inhibition Is Decreased at Higher Microvascular Density
The gray lines represent the case of 2% vascular volume (as depicted in Figure 4); the colored lines represent a 4.2% vascular volume. The peak
inhibition due to the blockade of VEGFR–Neuropilin coupling is the same for both vascular densities; however, the peak for the other two treatments is
lower. Endothelial cells expressing 10,000 VEGFR2 and 100,000 Neuropilin-1.
doi:10.1371/journal.pcbi.0020180.g009
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changes to the geometry of the tissue (i.e., to these geo-
metrical parameters) will result in changes to the effective
kinetic parameters, and to the concentrations of VEGF and
the complexes it forms with GAG chains or VEGF receptors.
Results of Computational Model Simulations
Simulations of VEGFR2 and Neuropilin coexpression.
Simulations of VEGF transport in breast cancer, and of
therapeutic interventions to inhibit signaling, were devel-
oped as described in the Methods section. The simulations
are ﬁrst presented with the endothelial cells of the blood
vessels expressing VEGFR2 and Neuropilin but not VEGFR1.
We will then examine the impact of VEGFR1 co-expression.
Blocking Neuropilin expression. Blockade of Neuropilin-1
synthesis results in a gradual decline in Neuropilin expression
on the endothelial cell surface (Figure 3G) as it is internalized
but not replaced by newly synthesized receptors. It reaches a
new steady state depending on the level of inhibition. This
decrease in Neuropilin expression results in a transient
decrease in VEGF–VEGFR2 formation (Figure 3A). The peak
inhibition of VEGF–VEGFR2 is dependent on the magnitude
of the decrease in Neuropilin-1 expression (and on the initial
Neuropilin expression), but for this set of parameters is
maximal at ;60% for complete knockdown. The effect is
transient, however, because the loss of Neuropilin reduces the
binding of VEGF165 to the VEGFR2 expressed on the
endothelial cells (Neuropilin has the effect of increasing the
amount of VEGF165 bound at a given extracellular VEGF
concentration). Less VEGF bound means less VEGF internal-
ized, and so the concentration of VEGF in the interstitial
space begins to increase as a result of the loss of Neuropilin-1
(Figure 3D). This increased interstitial VEGF concentration
results in increased VEGFR2 binding and signaling. The
system returns to a new ‘‘set point,’’ with a higher VEGF
interstitial concentration compensating for the loss of
Neuropilin. Thus, the long-term effect of total Neuropilin-1
loss is that VEGF165 behaves just as VEGF121 would if it were
secreted at the same rate (Figure 3D). VEGF121 and its
signaling are not affected by any of these treatments, and the
formation of VEGF121–VEGFR2 complexes is in each case the
same as for VEGF165 with no treatment.
Blocking VEGF–Neuropilin binding. Blockade of VEGF–
Neuropilin binding again results in a transient decrease in
the binding of VEGF165 to VEGFR2 (Figure 3B). A peak is
reached of 50% inhibition at 10 lM of the protein that blocks
VEGF binding. As for Neuropilin expression decrease, this
loss of VEGF binding and internalization leads to the buildup
of VEGF in the interstitial space (Figure 3E) and results in the
loss of the VEGF signaling inhibition. The initial concen-
tration of the inhibitor (PlGF2D) affects the transient. Note
that for higher initial concentrations of the inhibitor (1–10
DM), where the concentration of the inhibitor remains
essentially constant (Figure 3H), a constant inhibition of
VEGF signaling is not obtained. The inhibitor becomes
ineffective because the VEGF interstitial concentration
increases, and therefore the VEGF binding to VEGFR2
returns to its original level. A low concentration (100 nM)
results in depletion of the inhibitor through internalization
after 36 hours (Figure 3H). By the time the inhibitor is
depleted, and Neuropilin is available for binding again, VEGF
concentration has increased substantially (Figure 3E), and this
results in a transient overshoot in the binding of VEGF to
VEGFR2 (Figure 3B). Thus, signaling is transiently increased as
the system returns to its previous state, with VEGF concen-
tration declining to its original level (Figure 3E). This is not
observed in the Neuropilin expression blocking treatment as
the expression level remains low for the 48-hour duration of
the experiment.
Blocking VEGFR–Neuropilin coupling. Blockade of
VEGFR–Neuropilin coupling results in signiﬁcantly higher
peak inhibition than the ﬁrst two treatments: 80% at 1 lMo f
the Neuropilin-1 antibody (Figure 3C). In addition, the
inhibition is not transient, but sustained over the 48 hours
of the analysis, as long as the inhibitor is present in the
interstitial space (Figure 3I). For lower initial concentrations
of the inhibitor, the antibody is internalized and depleted
(after 32 hours), and the system returns to its original
signaling state at the same time (Figure 3C, 3F, 3I). There is a
slight increase in interstitial VEGF concentration in the
presence of the inhibitor (Figure 3F). This is due to decreased
internalization of VEGF as a result of lower total binding to
VEGFR2 and Neuropilin as result of the loss of coupling
(VEGFR2–Neuropilin coupling stabilizes VEGF165 association
with the cell surface). This increase in VEGF concentration
results in the transient overshoot observed in VEGF signaling
when the inhibitor is depleted (Figure 3C).
Summary of inhibition of VEGFR2 signaling. Our com-
puter simulations predict that the maximal average inhib-
ition of VEGF–VEGFR2 complex formation over the 48 hours
is less than 30% for Neuropilin-1 expression blocking or
VEGF binding blocking, but close to 80% for blocking
VEGFR–Neuropilin coupling (Figure 4). The blocking of
coupling is predicted to be particularly effective in inhibiting
VEGF signaling in vivo because Neuropilin-1 can still bind
VEGF on the surface of the endothelial cell. Other methods of
blocking Neuropilin-1 result in the functional absence of this
pro-angiogenic co-receptor; by blocking coupling, however,
we have turned Neuropilin-1 into an anti-angiogenic co-
receptor, sequestering VEGF on the surface away from the
signaling receptors.
While the blockade of VEGFR–Neuropilin coupling exhib-
its prolonged inhibition of VEGF–VEGFR2 binding (Figure
3C) compared with the other treatments (Figure 3A and 3B),
it does not automatically follow that this extended decrease
in signaling will result in increased inhibition of angiogenesis
and vascular growth, as timing of VEGF signaling, as well as
other cytokines, may play a role.
Effect of high VEGFR1 expression. Some tissues, but not
all, also demonstrate VEGFR1 expression on endothelial cells.
Unlike VEGFR2, VEGFR1 interacts directly with Neuropilin-
1, and the complex formed can bind VEGF121 but not
VEGF165 [45,46] (Figure 1B). Thus, the presence of Neuro-
pilin-1 diverts VEGF165 from binding VEGFR1 to binding
VEGFR2. In addition, VEGFR1 itself transduces VEGF signals,
though it appears that these may inhibit or modulate
VEGFR2 signaling [47]. Thus Neuropilin-1 increases VEGFR2
signaling both by presentation of VEGF165 and by inhibiting
binding of VEGF165 to VEGFR1. Since both of these processes
would be inhibited by blocking Neuropilin-1, we analyzed a
tissue that expressed high levels of VEGFR1 to determine the
effects of these treatments.
All three of the treatments now resulted in signiﬁcant,
sustained decreases in VEGF165 VEGFR2 signaling (Figure
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VEGFR1, which was not possible while Neuropilin-1 was
forming complexes with VEGFR1. With the Neuropilin-1
decreased or occupied, there is increased formation of
VEGF–VEGFR1 complexes (Figure 5D–5F). The inhibition
of VEGFR2 signaling that results from blocking Neuropilin-1
expression or VEGF binding in these tumors is not transient,
as the internalization of VEGF by VEGFR1 prevents
interstitial VEGF buildup as signiﬁcant as that in the absence
of VEGFR1 (compare Figure 5G–5I with Figure 3D–3F).
The result of functional Neuropilin-1 loss (by expression or
binding blockade) is, as before, that VEGF165 signaling
becomes similar to VEGF121 signaling. In tissues that express
VEGFR1 (with or without Neuropilin), most VEGF121 binds to
VEGFR1 (higher afﬁnity than VEGFR2), and, thus, the
VEGF121 signaling through VEGFR2 is decreased as the
receptors compete for the available ligand. Blockade of
VEGFR-Neuropilin coupling, on the other hand, results in a
decrease in VEGFR2 signaling beyond that of VEGF121
(Figure 5C). In addition to blocking VEGFR1-Neuropilin
coupling, it results in the sequestration of VEGF165 by the
nonsignaling Neuropilin-1. Thus, the model still predicts that
for tissues expressing high levels of VEGFR1 on blood vessels,
blocking coupling will be the most effective therapy, though
not by as great a margin (Figure 6).
Tumor speciﬁcity: Variation in receptor expression. The
vasculature in different tissues—and in different tumors—
expresses different amounts of each VEGF receptor. This can
result in differing responses to therapies. The tissue-speciﬁc
nature of these interactions is investigated by varying the
receptor expression of both Neuropilin-1 and VEGFR1
(Figure 7). The inhibition of VEGFR2 signaling by each of
the three treatments (Figure 7A–7C) is directly proportional
to Neuropilin-1 expression, and tissues that express only low
levels of Neuropilin-1 are predicted to be insensitive to these
treatments. Only at extremely high levels of Neuropilin
(above 10
6 per cell) can the vessels overcome the inhibition
and maintain functional involvement of Neuropilin in
VEGFR-signaling enhancement. VEGFR–Neuropilin coupling
blockade is the most effective treatment for all tissues (Figure
7C), though in tissues expressing high VEGFR1 on the
vasculature, the other treatments are also predicted to be
quite effective. Thus, it is essential to understand the
microenvironment of the tissue of action of the drug being
administered, as a drug that efﬁciently decreases VEGF
signaling in one tissue may not do so in another. In
particular, a method to measure the level of receptor
expression on cell surfaces in vivo would be helpful in
determining which tissues are suitable for which treatment.
It is important to note that for all endothelial cell types
that have been measured, from various different tissues, cell
surface VEGFR1 expression is equal to or less than VEGFR2
expression, which suggests that blocking receptor coupling
will be the most effective treatment.
VEGF–VEGFR1 binding is increased by each Neuropilin
treatment except for tissues expressing a high level of
VEGFR1 and a low level of Neuropilin-1 (Figure 7D–7F). In
these tissues, most Neuropilin is predicted to be normally
bound to VEGFR1, but there is excess VEGFR1, and blocking
the Neuropilin–VEGFR1 interaction does not substantially
increase the VEGF–VEGFR1 binding.
Larger vascular volume in tumor. The vascular volume
varies signiﬁcantly from tumor to tumor. Here we simulate a
tissue in which the vessels occupy 5% of the tissue volume
(the vascular space 4.2% of volume). For this simulation, the
vessel surface area is 218 cm
2/cm
3, and the volume of the
interstitial compartment is reduced slightly. The increased
vascularity also increases the total volume of endothelial
basement membrane. The increased vessel density results in
increased receptor density in the tissue, and so the inhibitors
are depleted more quickly (Figure 8H–8I). The peak
inhibition due to expression or binding blockade is lower
and more transient than before (Figure 8A–8B). The average
inhibition over the 48 hours of the simulation is lowered for
all treatments, except for high concentrations of the coupling
inhibitor (Figure 9).
Discussion
The vasculature that invests a tumor has been recognized as
a therapeutic target that can be exploited to starve the tumor
or to increase the delivery of drugs directly to the tumor [48];
vascular density is a negative prognostic factor for many
cancers, including breast cancer [36]. The VEGF family of
growth factors, and their receptors, are involved in the
process of angiogenic vessel growth in tumors, and targeting
these molecules may prove to be a successful anti-cancer
therapy.
We have previously built a computational model that
describes the behavior of the VEGF–VEGF receptor system
[9,13] and agrees with all available in vitro experimental
literature [10,14–16]. We have extended that model here to
simulation of an in vivo tissue to investigate the signaling of
VEGF through blood vessel endothelial cell surface receptors
in cancer. The model is generally applicable to most cancers,
given appropriate values for the parameters. Here the model
is applied to human breast cancer and the impact of several
treatments that target Neuropilin-1 to inhibit VEGF165
signaling. One of these therapeutic strategies, blockade of
VEGF receptor–Neuropilin coupling on the cell surface, is
predicted to be signiﬁcantly more effective and more
persistent than the others at all concentrations and for all
tissues studied. The effectiveness of this antibody to inhibit
pathological angiogenesis has been validated experimentally
[15]. In that case, the antibody inhibited neovascularization in
the eye, but our simulations predict that the antibody would
also be effective as an anti-tumor therapy, though this has yet
to be tested in vivo.
Thus, the model shows that it is not enough to identify
Neuropilin as a therapeutic target due to its speciﬁcity for
VEGF165; different methods of targeting Neuropilin result in
different outcomes.
It should be noted that here we deﬁne effectiveness as the
decrease in VEGF–VEGFR2 binding over the 48 hours
following treatment. Timing is a crucial component of
intracellular signaling, and it is not clear at this point
whether the prolonged inhibition of signaling (e.g., Figure 3C)
is more effective at inhibiting angiogenesis and vascular
growth than transient inhibition (e.g., Figure 3A–3B). In
addition, other cytokines could partly compensate for the loss
of VEGF–VEGFR2 signaling.
For VEGFR2, Neuropilin-1-expressing vasculature, inhib-
ition of VEGF–Neuropilin-1 binding, or Neuropilin-1 ex-
pression blockade result in transient VEGFR2-signaling
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Sustained high levels of the VEGF–Neuropilin-1 binding
inhibitor (or sustained depletion of Neuropilin from the
surface) in the interstitial space result in VEGF–VEGFR2
signaling recovering from the inhibition during the simu-
lation due to the increasing interstitial VEGF concentration.
The vasculature in different types of breast cancer
expresses different levels of VEGFR1, VEGFR2, and Neuro-
pilin-1. In fact, the expression of these receptors may vary
spatially within a tumor [49]. The effectiveness of each
treatment is predicted to be directly dependent on the
receptor expression proﬁle of the target tissue. Increased
Neuropilin results in increased efﬁcacy of anti-Neuropilin
therapy, except at very high Neuropilin levels, at which the
inhibition becomes ineffective. VEGFR1 coupled to Neuro-
pilin does not sequester VEGF165, and so the presence of
VEGFR1 affects the outcome of therapeutic interventions
signiﬁcantly. For application to other cancers, different
geometries would hold, and different expression levels of
the receptors. However, the basic molecular interactions
would be the same, and the qualitative conclusions of our
study can be generalized to other tumor types.
We have not included the effect of VEGF receptors on the
tumor cells themselves. This is increasingly being identiﬁed as
a source of autocrine survival and growth signaling for the
tumor cells. We focused instead on the impact on pro-
angiogenic signaling at the endothelial cell surface. Inclusion
of VEGF receptors on the tumor cells would not qualitatively
change our results. For example, the presence of Neuropilin
on tumor cells would offer an alternate route for VEGF (away
from the endothelial cells). Blockade of Neuropilin expres-
sion, or blocking VEGF–Neuropilin binding, would result in
the VEGF that normally binds to tumor cells being redirected
to the endothelial cells, possibly increasing pro-angiogenic
signaling. By contrast, blockade of VEGFR–Neuropilin
coupling would not have this problem, as VEGF165 could
continue to bind the Neuropilin receptors on tumor cells and
would not be displaced.
This model does not include pharmacokinetics—i.e., the
route by which the drugs would get to the tumor. It is only
concerned with their activity or efﬁcacy once present at the
tumor. As such, even for intratumoral injection, we assume
that none of the inhibitor is lost to the bloodstream or
lymphatics. Signiﬁcant loss of this type from the interstitial
space would decrease the efﬁcacy of each of these inhibitors.
In addition, vascular heterogeneity within a tumor is not
addressed in this study.
This is the ﬁrst computational model of VEGF transport in
vivo, and the ﬁrst molecularly detailed model of VEGF
inhibition strategies. Models such as this can also be used to
investigate other aspects of drug delivery, e.g., dosing and
scheduling, as they deal with the site of action of the drug.
Testable predictions of this model include the increase in
interstitial VEGF concentration in response to the admin-
istration of each of the therapeutic strategies, as well as the
characteristic signaling inhibition that could be detected at
the level of receptor phosphorylation. These predictions
should stimulate extensive experimental studies, and the
model presented here would serve as a quantitative guide to
experimental design.
For example, preclinical models of breast cancer could be
used to test the therapeutic strategies and validate the model.
Following characterization of breast cancer lines and their
induced vasculature, VEGFR2–NRP1 and VEGFR2–VEGFR1–
NRP1-expressing candidates would be selected for compar-
ison (Figures 3 and 5). After administration of each of the
therapies, the unbound interstitial concentration of VEGF
(Figure 3D–3F, Figure 5G–5I) and the phosphorylation level
of VEGFR2 (Figure 3A–3C, Figure 5A–5C) would be
measured at several time points and compared with controls.
Six, 12, 24, 36, and 48 hours appear to be relevant to the
dosing used in these simulations. These time points are
earlier than typical preclinical endpoints and are an example
of how the simulation results can help direct experimental
design. In these experimental results, we would expect to
observe the characteristically different behavior of each of
the therapeutics in VEGFR1-negative breast cancer (Figure
3), and their similarity in VEGFR1-positive breast cancer
(Figure 5).
Analogous to the drugs targeting Her2-positive breast
cancer that are not effective against Her2-negative breast
cancer [50], we demonstrate that the efﬁcacy of some anti-
angiogenic strategies will depend on the receptor expression
levels on the tumor-associated vasculature. For anti-Neuro-
pilin treatment, this includes not just Neuropilin expression,
but also that of its signaling co-receptors VEGFR1 and
VEGFR2. Analysis of a system such as this using computa-
tional or systems biology tools can provide signiﬁcant insights
into the success and failure of drugs targeting angiogenesis
and other processes, and aid in the design and optimization
of novel therapeutics. The proteins used in these simulations
are not the only proteins or drugs that would inhibit
Neuropilin; others may be designed or discovered with
similar properties, but the same principles would apply in
predicting efﬁcacy.
Materials and Methods
Model solution and simulations. Simulations of VEGF transport in
human breast cancer were developed based on the model described
in the Results section. The appropriate secretion rate for each
simulation was used to achieve a steady state, free (unbound) VEGF
concentration of 1pM. Then a therapeutic intervention was simulated
by changing appropriate parameters or introducing new molecular
species into the system. The complete set of coupled nonlinear
ordinary differential equations (see Results) were solved using a
Runge–Kutta integration scheme, implemented in Fortran, and run
on a desktop PC. The parameters used for these simulations are based
on experimental measurements, as detailed in the Results section.
Supporting Information
Accession Numbers
Accession numbers from UniProt (http://www.pir.uniprot.org/) are
Human VEGF-A (VEGF) (P15692), Human PlGF (P49763), Human
VEGFR1 (P17948), Human VEGFR2 (P35968), and Human Neuro-
pilin-1 (NRP1) (O14786).
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